Boehringer Ingelheim study underlines safety profile of Jardiance

Boehringer Ingelheim has announced the findings of a new analysis that reinforces the established safety profile of its type 2 diabetes therapy Jardiance.

The analysis of pooled safety data was published in the medical journal Advances in Therapy, and compiled data from 15 previous studies and four extension studies, involving more than 12,500 diabetic adults.

It was demonstrated that treatment with Jardiance was well-tolerated, with no imbalance in lower limb amputations or bone fractures compared with placebo. Boehringer Ingelheim's drug was also not shown to be associated with an increased risk of hypoglycaemia, except in those who were on background sulfonylurea therapy.

This analysis included a study of data from the EMPA-REG OUTCOME trial, which demonstrated that Jardiance reduced the risk of cardiovascular death by 38 percent versus placebo in people with type 2 diabetes and established cardiovascular disease, when added to the standard of care.

These findings will help to bolster confidence in those using and prescribing Jardiance, which has been approved for use in Europe, the US and other markets around the world for the treatment of type 2 diabetes for a number of years.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.